Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Update article

Viral metagenomics and blood safety

La métagénomique virale : un nouvel outil au service de la sécurité transfusionnelle

V. Sauvage\textsuperscript{a,\ast}, M. Eloit\textsuperscript{b,c}

\textsuperscript{a} Département d'études des agents transmissibles par le sang, Institut national de la transfusion sanguine (INTS), Centre national de référence des hépatites virales B et C et du VIH en transfusion, 75015 Paris, France
\textsuperscript{b} PathoQuest, bâtiment François-Jacob, 25, rue du Dr-Roux, 75015 Paris, France
\textsuperscript{c} Inserm U1117, Biology of Infection Unit, Laboratory of Pathogen Discovery, Institut Pasteur, 28, rue du Docteur-Roux, 75724 Paris, France

Available online 9 January 2016

This manuscript has been written in memory to Jean Jacques Lefrère.

Abstract

The characterization of the human blood-associated viral community (also called blood virome) is essential for epidemiological surveillance and to anticipate new potential threats for blood transfusion safety. Currently, the risk of blood-borne agent transmission of well-known viruses (HBV, HCV, HIV and HTLV) can be considered as under control in high-resource countries. However, other viruses unknown or unsuspected may be transmitted to recipients by blood-derived products. This is particularly relevant considering that a significant proportion of transfused patients are immunocompromised and more frequently subjected to fatal outcomes. Several measures to prevent transfusion transmission of unknown viruses have been implemented including the exclusion of at-risk donors, leukocyte reduction of donor blood, and physicochemical treatment of the different blood components. However, up to now there is no universal method for pathogen inactivation, which would be applicable for all types of blood components and, equally effective for all viral families. In addition, among available inactivation procedures of viral genomes, some of them are recognized to be less effective on non-enveloped viruses, and inadequate to inactivate higher viral titers in plasma pools or derivatives. Given this, there is the need to implement new methodologies for the discovery of unknown viruses that may affect blood transfusion. Viral metagenomics combined with High Throughput Sequencing appears as a promising approach for the identification and global surveillance of new and/or unexpected viruses that could impair blood transfusion safety.

© 2015 Elsevier Masson SAS. All rights reserved.

Keywords: Viral metagenomics; High Throughput Sequencing; Viral discovery; Blood-borne viruses; Emerging viruses; Blood safety

Résumé

Le risque transfusionnel infectieux lié aux virus connus (VHB, VHC, VIH et HTLV) peut être considéré à ce jour comme maîtrisé, en raison des mesures préventives prises par la plupart des pays à ressources élevées. En revanche, le risque potentiel persistant est lié à l’urgence d’agents infectieux, et en particulier viraux, non encore identifiés. Ceci est d’autant plus important qu’une proportion significative des patients transfusés sont immunodéprimés et donc plus exposés à des formes infectieuses graves dont l’issue peut être fatale. Plusieurs mesures visant à prévenir la transmission par transfusion de virus inconnus sont mises en œuvre tels que l’exclusion des donneurs à risque, la déleucocytation des plasmas, et le traitement physico-chimique des différents composants sanguins. Cependant, il n’existe pas à ce jour de méthode universelle pour l’inactivation des pathogènes, qui soit applicable à tous les types de composants sanguins et, tout aussi efficace pour toutes les familles virales. Par ailleurs, parmi les procédures d’inactivation des génomes viraux disponibles, certaines d’entre elles sont reconnues pour être moins efficaces sur les virus non

* Corresponding author.
E-mail address: vsauvage@ints.fr (V. Sauvage).

http://dx.doi.org/10.1016/j.tracli.2015.12.002

1246-7820 © 2015 Elsevier Masson SAS. All rights reserved.
1. Introduction

In developed countries, blood and organ donors are routinely screened for a range of blood-borne viruses (HIV, HBV, HCV and HTLV in some countries) with highly sensitive screening tests. This has dramatically improved the safety of blood supply. However, transmission by transfusion of unknown or unsuspected viruses, responsible for persistent and asymptomatic viremia, remains a continuing threat. This is particularly relevant considering that a significant proportion of transfused patients are immunocompromised and more frequently subjected to fatal outcomes. Several measures to prevent transfusion transmission of unknown viruses have been implemented including the exclusion of at-risk donors, leukocyte reduction of donor blood, and physicochemical treatments of the different blood components aimed to inactivate infectious agents potentially present in blood. However, up to now there is no universal method for pathogen inactivation, which would be applicable for all types of blood components (currently there is no method applicable for red blood cell concentrates) and, equally effective for all viral families [1]. Several inactivation procedures are available but some of them are recognized to be less effective on non-enveloped viruses, such as human parvovirus B19 (B19 V), Hepatitis A (HAV) or Hepatitis E (HEV) viruses [2]. Moreover, recent publications have also confirmed that some viral reduction methods (solvent/detergent and heat treatment) are inadequate to inactivate high viremic titers of these viruses in plasma pools or derivatives [3,4]. Given this, the threat for blood safety due to emerging viruses is of crucial importance. Thus, it remains imperative to improve the blood product safety, not only by surveillance of well-characterized viral pathogens (HBV, HCV, HIV, B19 V) but also, by implementing new methodologies for discovery of unknown viruses that may affect blood transfusion safety.

The recorded emergence of infectious diseases has risen significantly since the last three decades. In a period of 64 years (1940–2004) the emergence of 335 infectious diseases (all pathogens combined) was reported. Emerging infectious diseases (EIDs) are dominated by zoonoses, the majority of which (72%) has wildlife origin. The increasing and ongoing documentation of novel animal viruses identified worldwide predicts that additional animal pathogens may jump species barrier to potentially become novel human infectious diseases in the near future, some perhaps highly pathogenic. Viruses account for 25–44% of all EIDs [5] and are the pathogen class most likely to emerge [6] with an estimated number of undiscovered mammalian viruses of at least 320,000 [7]. This estimation suggests that zoonotic EIDs represent a serious threat to human health and emphasizes the importance to evaluate the factors that are involved in the contact between human and animals, responsible for the emergence of “zoonotic-human” infections [5]. Among some recent examples of viral emergence by host switching, with great impact on the public health, are the HIV pandemic (Europe, 1981; Central Africa, 1983), Severe Acute Respiratory Syndrome (SARS) caused by coronavirus (SARS-CoV, China, 2003) and Middle East Respiratory Syndrome (MERS) caused by MERS coronavirus (MERS-CoV, Saudi Arabia, 2013). Other examples include the extreme genetic variability of RNA influenza viruses like the emergence of highly virulent types like H5N1 (since 2003, China), pandemic H1N1 (Veracruz, Mexico, 2009–2010) and more recently a more virulent H7N9 influenza A virus (2013, China). These examples demonstrate that emergent diseases can easily overcome country boundaries, and even continents by means of infected travelers or international trade of livestock or plants. Many factors can contribute to the emergence and the spread of a novel infectious agent [8], as the increasing contact between humans and wildlife habitats mainly due to agricultural practices and the globalization of travel and trade. Other important factors include climate changes that promote vector expansion (mosquitoes, ticks) and mass human migrations (due to wars, natural disasters, poverty, and desertification) [9]. For these reasons, there is now a clear increased risk of arbovirus emergence in the future due to environmental and climate changes, extensive tropical urbanization and to the colonization of this expanding habitat by highly anthropophilic mosquitoes (i.e. Chikungunya and dengue viruses both transmitted by Aedes aegypti). To date, dengue viruses are internationally recognized as an existing threat to blood safety due to a known transfusion-transmission and severe/fatal disease in recipients [10]. As all arboviruses are potentially transmissible by transfusion due to their capacity to induce an asymptomatic viremic phase, this represents new risks for blood safety.

In the last years, very broad and sensitive high throughput techniques based on metagenomics were developed to detect and characterize previously unknown or variant viruses associated with several human diseases. These methods based on the random amplification of genomes include pan-viral microarrays and High Throughput Sequencing (HTS) [11]. By overcoming conventional methods of viral identification, metagenomics, which gives access to all nucleic acids present in a given sample, allows the description of viral communities and their diversity in environmental [12,13], human [14–16] and animal samples [17–19] using HTS. Metagenomic sequencing has also demonstrated its usefulness in investigations when infectious diseases have
unknown etiology, as reported in human Merkel cell carcinoma for which a polyomavirus was identified as responsible [20], for the thrombocytopenia and leukopenia syndrome in China associated with a new bunyavirus [21] and for acute hemorrhagic fever outbreaks in Uganda [22] and Central Africa [23] due to new Ebola virus and rhabdovirus, respectively. This approach has also been used to identify novel viruses responsible of severe or fatal post-transplant associated diseases in grafted recipients [24,25]. Besides the development of metagenomics as a diagnostic tool in clinical virology [26,27], this methodology was applied to viral safety for biotechnological and biological products [28,29]. Using metagenomics, it is then possible to provide manufacturers the exhaustive viral bioburden of raw materials [30–34] and to detect adventitious viruses in live-attenuated vaccines [35].

With more than 3 million blood components transfused annually in France alone, viral metagenomics appears as a promising approach for the identification and global surveillance of new and/or (re)-emerging viruses that could impair blood transfusion safety.

2. Pipeline of a metagenomic analysis: from the sample preparation until the bioinformatic analysis of raw sequencing data

Metagenomic sequencing offers the considerable advantage compared to traditional methods of pathogen identification of being a molecular approach able to detect simultaneously multiple organisms in a complex sample without culturing and a priori knowledge of the microorganism’s nucleic acid sequences. However, the application of viral metagenomics to clinical samples is made difficult by the fact that viral sequences represent a very low proportion compared to host DNA sequences and transcripts, bacterial and other contaminating genetic material (e.g. from environment and reagent). This leads to the requirement of high depth of sequencing and intensive bioinformatic analyses to increase the probability of virus detection. Despite the fact that amplification method, library construction and sequencing platform impact metagenome composition [36–40], adequate sample preparation enhancing the ratio of viral to host nucleic acid loads remains a crucial step for biological samples. The pipeline presented below comprises key steps and recommendations for viral metagenomic analyses, especially as applied to plasma or serum sample (Fig. 1).

3. Sample preparation

In order to increase the proportion of viruses, different purification and enrichment strategies can be applied on plasma samples prior sequencing, such as clearing centrifugation at low speed, membrane filtration (0.45 μm and/or 0.2 μm filter), ultracentrifugation, polyethylene glycol (PEG) virus precipitation, digestion of host cell-free DNA/RNA by nuclease(s) treatment and the removal of ribosomal RNA. These different techniques may be combined to maximize the amount of viral nucleic acids after extraction [39,41–43]. All viral metagenomic studies agree on the fact that nuclease(s) pretreatment of biological sample is an essential step to importantly reduce the amount of background nucleic acids.

Different manual and automated methods to extract viral nucleic acids can be used (Fig. 1) and require choosing between extracting DNA and RNA simultaneously or independently. Since (re)emerging viral threats are mainly caused by RNA viruses [5,44], viral nucleic acid isolation can be performed using TRIzol LS (Life Technologies) or reagents designed to obtain high quality RNA molecules in high yields. Following viral particles lysis and nucleic acid precipitation steps, viral genomic RNAs are purified using a spin column. Residual host and/or viral DNA are then removed by an additional DNase digestion is performed directly on the silica membrane or the final eluate. In some protocol, unwanted ribosomal RNAs are also removed after RNA purification [43], but removing ribosomal RNA at this stage by capture probes hybridization may cause viral sequences loss, especially those from unknown viruses. In addition, TRIzol extraction method offers the possibility to recover DNA virus genomes from the organic phase.

Once nucleic acids are extracted, RNAs are converted into single-stranded complementary DNA (ss cDNA) and randomly amplified together with DNA (if DNA and RNA were extracted simultaneously) to obtain the concentration required for library construction (1 μg to 1 ng depending on library preparation kits and sequencing platform). Number of sequence-independent amplification methods have been developed and used in combination with HTS for virus discovery. The most common are the sequence-independent single-primer amplification (SISPA) [45,46], Multiple Displacement Amplification (MDA) [36,47] and cDNA Amplified Fragment Length Polymorphism (cDNA-AFLP) [48]. These three methodologies can amplify simultaneously cDNA and DNA, linear and circular, single- and double-stranded viral genomes in a same sample. The SISPA method is extensively used by a number of laboratories in the world and allowed the identification of many new viruses in animal [49–51] and human clinical samples in the last ten years [23,52–54]. Compared to SISPA, MDA uses bacteriophage Phi29 polymerase. The MDA process presents the disadvantage to preferentially amplify circular ss DNA than linear viral genomes and thereby introduced a bias of amplification. However, this limitation does not prevent the detection of known RNA viruses [29,36,55] even at low concentrations (around 500–1000 copies/mL), and the discovery of new ones in biological samples [56]. Recently, MDA was successfully used in combination with HTS to discover a novel human astrovirus associated with a case of progressive encephalitis in a boy with X-linked agammaglobulinemia [57]. The cDNA-AFLP method was developed by Bachem et al. [58] and adapted for virus discovery (VIDISCA method) by van der Hoek et al. [59] for successful identification of a novel human coronavirus, HCoV-NL63, in a child suffering from bronchiolitis and conjunctivitis. Later, VIDISCA was used to discover novel paroviruses [60,61] and papillomavirus [62] in veterinary and clinical human samples, respectively.

Despite the efficiency of nuclease(s) pretreatment to decrease the host background, a significant proportion of reads after deep sequencing always correspond to host genome and
transcripts. To increase the sensitivity of virus detection required for clinical applications, several methods were developed to selectively hybridize and amplify non-human sequences. Of them, the “virome capture sequencing platform for vertebrate viruses” (VirCapSeq-VERT) [63], which comprises around 2 million probes covering all viral taxa known to infect vertebrates, the “Preferential Amplification of Pathogenic Sequences” (PATHseq) based on oligonucleotides that do not match the most abundant human transcripts [64] and the modified VIDISCA method using random hexamers that do not anneal to tRNAs [65,66]. Today, VirCapSeq-VERT in combination with Illumina HiSeq appears to be the most sensitive
method as it enabled detection of HHV-1 and West Nile Virus genomes, and enterovirus D68 at concentrations corresponding to 100 and 10 copies/mL, respectively, in human blood and serum samples [63]. Furthermore, according to the authors, the method can detect a virus whose genome is 40% different to the probe sequence, making this method a suitable tool for viral discovery. However, this method is extremely time-consuming (hybridization step > 12 h) and, therefore, non-appropriate for clinical diagnostic applications.

Finally, particular precautions to avoid contamination of samples, nucleic acid extracts and amplification products by exogenous nucleic acids must be implemented throughout the process including ultra-violet light treatment of some kit reagents, substitution of commercial carrier RNA kits by neutral chemical carriers such as linear polyacrylamide (LPA) and good laboratory practices compliance.

4. Library construction

Following reverse transcription and amplification steps, the resulting ds DNAs are sheared into defined DNA fragment size according to the sequencing platform by using enzymatic (e.g. Illumina Nextera® technology) or mechanical techniques (e.g. ultrasonic fragmentation with the Bioruptor [Diagenode] or the Covaris E210 [Covaris] systems). The extremities of fragmented DNA are end-repaired (mechanical shearing only) and ligated to specific sequencing adapters, which can be barcoded to allow multiplexing of several samples in a same sequencing run. Adapter-ligated DNAs are then size purified (e.g. Agencourt AMPure XP beads from Beckman Coulter) to select the properly ligated DNA. A reconditioning step corresponding to few cycles of amplification (5–16 cycles according to the sequencing chemistry) can be performed. This adaptor-mediated amplification step is used to increase product yield and enrich for DNA fragments with the appropriate adapters combination for optimal sequencing (Fig. 1). The library is then quantified by a fluorimetric-based method (e.g. Qubit®, Life Technologies or quantitative real-time PCR) and quality controlled with 2100 Bioanalyzer® (Agilent Technologies) to confirm the library size.

It should be noted that the choice of the library preparation method depends in part on the input DNA amount. For example, Illumina TruSeq® DNA PCR-Free library preparation kit (based on mechanical fragmentation) requires 1–2 μg of input DNA, while Illumina Nextera® technology uses 1–50 ng of DNA. For Ion Torrent Technology, the library preparation kit based on enzymatic shearing (Ion Xpress® from Life Technologies) requires a minimum of 50–100 ng. With the recent development of library preparation kits (e.g. Illumina Nextera XT® DNA) from very low input DNA (< 1 ng), non-amplified ds DNA can be directly fragmented, associated to adapters and PCR amplified to obtain the required DNA concentration for sequencing. Removing the non-specific preamplification step significantly reduces duplicated sequences, and thus increases the genome coverage and the number of viruses detected [67]. Likewise, the linker-amplified (LA) protocol in combination with optimal sample preparation for viruses enabled detection of viral sequences from 1–10 pg of input DNA [37,68], even if is not recommended by the manufacturers.

The resulting libraries can be sequenced following the manufacturer’s protocol for each of the sequencing platforms.

5. Template preparation and High Throughput Sequencing

Novel sequencing technologies that are currently available comprise second- and third-single molecule generation of sequencers. Second-generation sequencers are currently the most widely used and include the Genome Analyzer (GA)/HiSeq/NextSeq/MiSeq from Illumina, GS FLX System/GS Junior from Roche (whose marketing will be stopped mid-2016) and the Ion Personal Genome Machine (PGM)/Ion Proton from Ion Torrent (Life Technologies) (Table 1). Note that Ion Torrent recently launched (September 2015) a newest sequencer, the Ion S5 instrument (Table 1), which offers in a unique device, chips with output (number of reads) and read lengths comparable to those of the Ion PGM and the Ion Proton (e.g. the 520 and 540 chips on S5 system are similar to the 318 chip on the PGM and the PI chip on the Proton, respectively). While the second-generation platforms present distinct sequencing chemistries and detection technologies [69], the sequencing workflow is based for all on libraries amplification to produce clonal clusters and sequencing using massive parallel synthesis (Fig. 1). On the other hand, given the number of second-generation sequencers, several factors must be considered in the choice of the technology, including cost performance, run time, output, flexibility, convenience and type of application. For example, the desktop sequencers, such as the Illumina MiSeq and the Ion Torrent PGM (both launched in 2011), are positioned for rapid targeted resequencing [70,71], and whole viral [72,73] and bacterial genome sequencing [74,75]. While they are both also used for metagenomic analysis [38,76–78], they offer a lower depth of sequencing (25 million reads per run for the MiSeq and 5–6 million reads for the Ion PGM) compared to the Illumina HiSeq (3 billion pair-end reads) and the Ion Proton (60–80 million reads with Ion PI chip), which therefore are more appropriate for whole metagenomics. Nowadays, the number of scientific publications using HiSeq instrument is considerably higher than those using Ion Proton, which is mainly attributable to its recent availability (September 2012) and lower capacity in terms of samples multiplexing (Ion PII chip announced for 2016 (but needs confirmation), will increase Ion Proton throughput to 300 million reads per run). However, the Ion Proton is a much more affordable, faster and compact system, theoretically capable of generating long reads (400 bp announced in 2016 but needs confirmation) compared to the HiSeq instrument. Recently, this platform was successfully used in viral metagenomics to identify two novel papillomaviruses in the vaginal microbiome of HIV positive women [79] and to detect different known viruses in plasma samples spiked at low viral concentrations [29].

To date, the use of the third generation of sequencers in viral metagenomics remains anecdotal [80,81]. Third-generation sequencers include the Single-Molecule Real-Time technology (SMRT) from Pacific Biosciences with the PacBio RS II
Table 1
Features of the most commonly used next-generation sequencing platforms in research and clinical diagnostic laboratories.

| Desktop sequencers | Massively parallel sequencers |
|--------------------|-------------------------------|
| MiSeq Illumina (2011) | Ion S5 System Ion Torrent (2011) |
| NextSeq 500 Illumina (2014) | Ion Proton Ion Torrent (2012) |
| MiSeq Illumina (2011) | HiSeq 2500 Illumina (upgrade HiSeq 2000) |

| Maximum read length | Single-lane flow cell | 4-lane flow cell |
|---------------------|-----------------------|------------------|
| MiSeq               | 2 × 300b              | 2 × 150b         |
| NextSeq 500        |                       |                  |
| Ion PGM Ion Torrent (2011) | Ion 314 chip | Up to 400b |
| Ion Torrent (2011) | Ion 316 chip | Up to 400b |
| Ion Torrent (2011) | Ion 318 chip | Up to 400b |
| Ion 520 Chip       | Up to 400b            |
| Ion 530 chip       | Up to 400b            |
| Ion 540 chip       | Up to 200b            |
| Ion PI chip        | Up to 200b (400b, 2016) |
| Ion PII chip       | 8-lane flow cell 2 × 100b |

| Number of single reads | 25Mb | 130Mb |
|------------------------|------|-------|
| Output/run             | 15Gb | 39Gb  |
| Run time               | 55 hrs | 26 hrs |

| Applications | Human whole genome | Exome | Small genome | Targeted | Transcriptome | ChIP-Seq | 16S Metagenomics | Whole metagenomics |
|--------------|--------------------|-------|--------------|----------|--------------|----------|-----------------|-------------------|
|             | x                  | x     | x            | x        | x            | x        | x               | x                 |
|             | x                  | x     | x            | x        | x            | x        | x               | x                 |
|             | x                  | O     | O            | O        | O            | O        | O               | O                 |
|             | x                  | x     | x            | x        | x            | x        | x               | x                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |
|             | O                  | O     | O            | O        | O            | O        | O               | O                 |

**b:** base; **M:** million; **b:** billion.

* Mid mode.

* High output mode with v3 chemistry.
system and the Nanopore sequencing technology from Oxford Nanopore Technologies with the MinION and PromethION devices (currently in prerelease testing through the MinION and PromethION Access Programmes). Compared to the previous generation, the third generation is characterized by the absence of template amplification prior sequencing (and for this reason it’s also called single-molecule sequencing), a signal registered in real-time and the ability to read long DNA fragments (several kilobases). Although obtaining long reads is revolutionary, these platforms still suffer from lower accuracy and the need of high input amounts of DNA (at least for MinION device according to our experience). However, the newest SMRT sequencer, the Sequel System (announced in September 2015 by Pacific Biosciences), may provide higher accuracy and throughput compared to PacBioRS II. The continuous performance improvements made by these two companies should secure an important place for these technologies in the field of viral metagenomics in the near future.

6. Bioinformatic analysis of raw reads

There are a lot of different pipelines that can be used for viral metagenomics. Basically, reads are first trimmed for quality and often, at least for the Illumina technology, duplicates (i.e. identical reads) are suppressed. In a second step, reads are filtered against the host human genome with a high stringency, meaning that in principle only human sequences are removed. There are then two possibilities.

There is often a step of assembly of single reads into contigs. Use of contigs allows for identifying hits with distant identities that would not have been distinguished from background on short single reads. As reads from new generation of sequencers become longer and longer, the need for assembly should decrease. Assembly of metagenomic reads into contigs poses specific difficulties due to the uneven abundance and thus coverage of viral species; moreover, random amplification also leads to uneven coverage of each genomes, the combination of both heterogeneity increasing the difficulty for assembly (see discussions on the tools in [82,83]). The following step is to conduct a blast analysis against a comprehensive database like the NCBI nr database and to identify sequences with a virus as best hit (a less resource demanding protocol is to blast first a viral database like NCBI vrl and then confirm viral best hits by checking them against the NCBI nr). Blast analysis can be done with singletons and also with reads assembled into contigs. For contigs non assigned at the nucleotide level, a protein Blast (Blastx) can be used. Results need to be carefully screened by a virologist with some practical experience in metagenomic analysis, as there are frequent false positive results when the blast is conducted with a high e-value. Coverage of the putative viral genome is a good criterion to assess the pertinence of identification of new viral sequences.

A second possibility is to map the reads against a database of viruses using stringent rules and thus identify known viruses (already present in databases) and close relatives. This type of pipeline is quicker as less resource-demanding and is particularly well suited for diagnostic or as a first comprehensive filter before more demanding Blast analysis (see, for example, the computational pipeline SURPI [84]).

7. Viral metagenomics applied to plasma samples from blood donors and recipients

Viral metagenomics associated with HTS has successfully demonstrated its capacity to detect and discover viruses in complex biological samples such as serum and plasma, and therefore appears as a promising approach for the identification and surveillance of unknown or unexpected viruses that may be transmitted to recipients by blood products.

To further assess the performance and the limits of this methodology, we recently conducted a metagenomic analysis on plasma-pooled samples collected from at risk subjects, including recipients of multiple blood transfusions and HBV-, HCV- and HIV-infected blood donors. A large amount of various viral sequences has been found in all pools, among which, anelloviruses and human pegivirus (HPgV), formerly known as GB virus C, were the most frequently identified agents. The presence of HBV DNA and HCV RNA was confirmed in plasma pools from blood donors previously found HBV or HCV infected. In these plasma pools, HBV DNA and HCV RNA accounted for $3.8 \times 10^{5}$ IU/mL and $1.7 \times 10^{6}$ IU/mL, respectively. In contrast, HIV RNA accounting for 150 copies/mL in the pool, was not detected (data not published). We also detected numerous short nucleotide sequences distinctly related to viral sequences reported in the current databases, and for which it was not possible to know if they represent bona fide viruses or they derive from other organisms. Despite the inclusion of at risk individuals and the efficacy of the pipeline to discover new viruses [36,56,85,86], no sequence suggestive of a new viral species was identified in the plasma samples analyzed in the study. Hence, these findings confirmed that viral metagenomics combined to HTS is able to identify the viral diversity present in blood samples, but also highlighted the difficulty to detect low levels of virus (lower than 500 equivalent genome/mL at the time of the study) and underlined some other issues including uncertainty of taxonomic assignment of short sequences and reagent contaminants. For instance, we retrieved sequences from the Parvovirus-like hybrid genome (PHV/NIH-CQV) in all pools, which although initially described as a possible new causative agent of seronegative hepatitis [87], was actually found as a background contaminant in water eluted from some nucleic acid extraction silica-binding columns [88,89]. Other viral contaminants from spin columns including circoviruses/densoviruses and iridoviruses were also previously reported [15]. All together, these findings demonstrate that HTS results must be interpreted with caution before discovery of a new virus is claimed.

Interestingly, Laoupouche et al. [90] reported during the XXVIth National Congress of the French Society of Blood Transfusion, the detection of Human astrovirus-MLB2 sequences in transfusion plasma. Human astroviruses are known as important agents of viral gastroenteritis, especially in young children, elderly and immunocompromised individuals [91]. The Human astrovirus-MLB2 was initially discovered in diarrheal stools of children from India and the United States [92],
and it has since been detected in the plasma of a febrile child [93], suggesting that astrovirus-MLB2 may spread from gastrointestinal tract to other tissues via the bloodstream. Several recent studies have reported the potential association of a new clade of astroviruses with neurological diseases and especially with encephalitis cases in both animals [94] and immunocompromised individuals [95,96]. In humans, the latest reported case concerned a boy with X-linked agammaglobulinemia associated with progressive global motor decline, cerebellar syndrome, and epilepsy, who was found to be infected with a new astrovirus strain from the VA1/HMO clade [57]. Reports of astrovirus-associated encephalitis were also described in allogeneic hematopoietic stem cells [97] and bone marrow transplant recipients [98]. These examples clearly demonstrate the usefulness of viral metagenomic sequencing for the diagnosis of unexpected viral infections.

Other examples of viruses recently described in human blood samples by metagenomics and HTS can be cited such as the human hepegivirus 1 (HHPgV-1), discovered in post-transfusion serum samples from blood recipients [99]; a divergent Gemycirculavirus (GemyC1c), found in an HIV1-positive blood donation [100]; and Giant Blood Marseillevirus (GBM), discovered initially in a pool of samples collected from asymptomatic blood donors from the South of France [101] and subsequently found by PCR in 4% of 174 studied healthy donors and in 9.1% of post-transfusion sera from thalassemia patients [102]. However, in two recent studies reported (339 [103] and 187 [104] subjects, respectively), GBM viral DNA was not detected by PCR in any of the human plasma samples analyzed. Further investigations are needed to confirm the reality of these novel viral infections in humans, their potential pathogenicity and transfusion transmissibility.

8. Conclusion

Despite the undeniable analytical strength of this methodology, further investigations of the blood virome in a research context are needed to enforce the potential use of viral metagenomics and HTS for the discovery and surveillance of viruses of concern in blood safety.

As it is unlikely that the first occurrence of an emerging infection will be seen in transfused recipients, it is of paramount importance to implement a proactive surveillance of emerging viral infections in blood donor populations from different parts of the world especially from geographic areas with the highest rates of EIDs. After the identification of a new agent, if any, a process for evaluating its transmission routes by blood transfusion and its potential pathogenicity according to the immune status of the recipients will be implemented. Moreover, the risk assessment will help to define the need for implementation of new preventive strategies to reduce the transfusion transmission risk associated to this emerging agent. Such project will generate several recommendations to help health authorities to issue guidelines. This approach will become part of blood safety vigilance and will be extended to address more general public health issues regarding emerging infectious agents.

Disclosure of interest

VS declares that she has no competing interest. ME is CSO of a spin out of Institut Pasteur, PathoQuest, dedicated to the diagnostic of infectious diseases by Next Generation Sequencing.

Acknowledgements

Our thoughts are with Jean-Jacques Lefrère. We thank Syria Laperche for her confidence.

References

[1] Barros AE, Gomes AM, do Bonfin CV. Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids. Rev Bras Hematol Hemoter 2012;34:231–5.
[2] Hauser L, Roque-Afonso AM, Beylouné A, Simonet M, Deau Fischer B, Burin des Roziers N, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014;123:796–7.
[3] Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49:1S–29S.
[4] Zhang W, Ke L, Changqing L, Zhang Y, Li W. Parvovirus B19 V DNA contamination in Chinese plasma and plasma derivatives. J Transl Med 2012;10:194.
[5] Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman J, et al. Global trends in emerging infectious diseases. Nature 2008;451:990–3.
[6] Cleaveland S, Haydon DT, Taylor L. Overviews of pathogen emergence: which pathogens emerge, when and why? Curr Top Microbiol Immunol 2007;315:85–111 [Review].
[7] Anthony SJ, Epstein JH, Murray KA, Navarrete-Macias I, Zambrana-Torrelio CM, Solovyov A, et al. A strategy to estimate unknown viral diversity in mammals. MBio 2013;4:e00598–613.
[8] Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature 2007;447:279–83.
[9] Lipkin WI. The changing face of pathogen discovery and surveillance. Nat Rev Microbiol 2013;11:133–41.
[10] Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014;9:30–6.
[11] Tang P, Chiu C. Metagenomics for the discovery of novel human viruses. Future Microbiol 2010;5:177–89.
[12] Ng TF, Marine R, Wang C, Simmonds P, Kapusinzky B, Bodhidatta L, et al. High variety of known and new RNA and DNA viruses of diverse origins in untreated sewage. J Virol 2012;86:12161–75.
[13] Labonté JM, Suttle CA. Previously unknown and highly divergent ssDNA viruses populate the oceans. ISME J 2013;7:2169–77.
[14] Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GD, et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 2011;21:1616–25.
[15] Lysholm F, Wetterbom A, Lindau C, Darhan B, Bjerkner A, Fahrlander K, et al. Characterization of the viral microbiome in patients with severe lower respiratory tract infections, using metagenomic sequencing. PLoS One 2012;7:e38075.
[16] Fournolge V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. PLoS One 2012;7:e38499.
[17] Pan TG, Kapusinzky B, Wang C, Rose RK, Lipton HL, Delwart EL. The fecal viral flora of wild rodents. PLoS Pathog 2011;7:e100219.
[18] Shain T, Li L, Simmonds P, Wang C, Moeser A, Delwart E. The fecal virome of pigs on a high-density farm. J Virol 2011;85:11697–708.
[19] Dacheix L, Cervantes-Gonzalez M, Guigon G, Thibierge JM, Vandembogaert M, Maurais C, et al. A preliminary study of viral metagenomics of
French bat species in contact with humans: identification of new mammalian viruses. PLoS One 2014;9:e87194.

[20] Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096–100.

[21] Xu B, Liu L, Huang X, Ma H, Zhang Y, Du Y, et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus. PLoS Pathog 2011;7:e1002369.

[22] Towner JS, Sealy TK, Khristova ML, Albariño CG, Conlan S, Reeder SA, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4:e1000212.

[23] Grand G, Fair JN, Lui D, Slikas E, Steffen I, Muyembe JJ, et al. A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog 2012;8:e1002924.

[24] Mishra N, Pereira M, Rhodes RH, An P, Pipas JM, Jain K, et al. Identification of a novel polyomavirus in a pancreatic transplant recipient with retinal blindness and vasculitic myopathy. J Infect Dis 2014;210:1595–9.

[25] Palacios G, Druce D, Du L, Tran T, Birch C, Briese T, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008;358:991–8.

[26] Barzon L, Lavezzo E, Costanzi G, Franchin E, Toppo S, Pâlu G. Next-generation sequencing technologies in diagnostic virology. J. Clin. Virol. 2013;58:346–50.

[27] Quiliones-Mateu ME, Avila S, Reyes-Teran G, Martinez MA. Deep sequencing: becoming a critical tool in clinical virology. J Clin Virol 2014;61:9–19.

[28] Onions D. Overview of emerging technologies to detect adventitious agents. PDA J Pharm Sci Technol 2011;65:654–9.

[29] Cabannes E, Hébert C, Eloit M. Whole genome: next-generation sequencing as a virus safety test for biotechnological products. PDA J Pharm Sci Technol 2014;68:631–8.

[30] Onions D, Côté C, Love B, Toms B, Koduri S, Armstrong A, et al. Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome. Vaccine 2011:29:7117–21.

[31] Onions D. Massively parallel sequencing: a new tool in virus discovery and vaccine safety. Bull Mem Acad R Med Belg 2011;166:404–6.

[32] Gagnier L, Cheval J, Gratigny M, Hébert C, Muth E, Dumarest M, et al. Unbiased analysis by high throughput sequencing of the viral diversity in fetal bovine serum and trypsin used in cell culture. Biologicals 2014;42:145–52.

[33] Gagnier L, Cheval J, Crochet M, Bredat E, Gratigny M, Hébert C, et al. Analysis by high throughput sequencing of Specific Pathogen Free eggs. Biologicals 2014;42:218–9.

[34] Dumarest M, Muth E, Cheval J, Gratigny M, Hébert C, Gagnier L, et al. Viral diversity in swine intestinal mucus used for the manufacture of heparin as analyzed by high-throughput sequencing. Biologicals 2015:43:31–10.

[35] Victoria JG, Wang C, Jones MS, Jaing C, McLaughlin K, Gardner S, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010;84:6033–40.

[36] Cheval J, Sauvage V, Frangeul L, Dacheux L, Guigon G, Dumey N, et al. Evaluation of high-throughput sequencing for identifying known and unknown viruses in biological samples. J Clin Microbiol 2011;49:3268–75.

[37] Solonenko SA, Ignacio-Espinoza JC, Alberti A, Cruad C, Hallam S, Konstantimdis K, et al. Sequencing platform and library preparation choices impact viral metagenomes. BMC Genomics 2013;14:320.

[38] Greninger AL, Herring BL, Russell RC, Doggett SL, et al. Enhanced arbovirus surveillance with deep sequencing: Identification of novel rhabdoviruses and bunyaviruses in Australian mosquitoes. Virology 2014;448:146–58.

[39] McMullan LK, Page BL, Grogan AL, Herring BL, Russell RC, Doggett SL, et al. Enhanced arbovirus surveillance with deep sequencing: Identification of novel rhabdoviruses and bunyaviruses in Asian mosquitoes. PLoS Pathog 2009;5:e1000455.

[40] McMullan LK, Frace M, Sammons SA, Shoemaker T, Balinandi S, Wamala JF, et al. Using next generation sequencing to identify yellow fever virus in Uganda. Virology 2012;422:10036–46.

[41] Sauvage V, Ar Gouilh M, Cheval J, Muth E, Pariente K, Burguiera A, et al. A member of a new Picornaviridae genus is shed in pig feces. J Virol 2012;86:10036–46.

[42] Frémond ML, Pérot P, Muth E, Cros G, Muth E, Dumarest M, Mahlaoui N, et al. Enhanced arbovirus surveillance with deep sequencing: Identification of novel rhabdoviruses and bunyaviruses in African mosquitoes. PLoS Pathog 2009;5:e1000455.

[43] McMullan LK, Frace M, Sammons SA, Shoemaker T, Balinandi S, Wamala JF, et al. Using next generation sequencing to identify yellow fever virus in Uganda. Virology 2012;422:1–5.

[44] Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Cordere T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect 2014;20:O656–63.

[45] Sauvage V, Ar Gouilh M, Cheval J, Muth E, Pariente K, Burguiera A, et al. A member of a new Picornaviridae genus is shed in pig feces. J Virol 2012;86:10036–46.
[62] Canuti M, DeJis M, Jazaeri Farsani SM, Holwerda M, Jebbink MF, de Vries M, et al. Metagenomic analysis of a sample from a patient with respiratory tract infection reveals the presence of a γ-papillomavirus. Front Microbiol 2014;5:347.

[63] Brieze T, Kapoor A, Mishra N, Jain K, Kumar A, Labado OI, et al. Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis. MBio 2015;6:e01491–15.

[64] Ge F, Parker J, Chul Choi S, Layer M, Ross K, Jilly B, et al. Preferential amplification of pathogenic sequences. Sci Rep 2015;5:11047.

[65] de Vries M, DeJis M, Canuti M, van Schaik BD, Faria NR, van de Garde MD, et al. A sensitive assay for virus discovery in respiratory clinical samples. PLoS One 2011;6:e16118.

[66] de Vries M, Ouode Munnink BB, DeJis M, Canuti M, Koeklokoek R, Molenkamp R, et al. Performance of VIDISCA-454 in feces-suspensions and serum. Viruses 2012;4:1328–34.

[67] Li L, Deng X, Mee ET, Collot-Teixeira S, Anderson R, Schepelmann S, et al. Comparing viral metagenomics methods using a highly multiplexed human viral pathogens reagent. J Virol Methods 2015;213:139–46.

[68] Duhaime MB, Deng L, Poulos BT, Sullivan MB. Towards quantitative metagenomics of wild viruses and other ultra-low concentration DNA samples: a rigorous assessment and optimization of the linker amplification method. Environ Microbiol 2012;14:2526–37.

[69] Buermans HP, den Dunnen JT. Next generation sequencing technology: advances and applications. Biochim Biophys Acta 2014;1842:1932–41.

[70] Widarsari Dl, Yano Y, Heriyanto DS, Utsumi T, Yamani LN, Rinonce HT, et al. A deep-sequencing method detects drug-resistant mutations in the hepatitis B virus in Indonesia. Internuvirology 2015;57:384–92.

[71] Rego FF, de Oliveira T, Giovanetti M, Galvão-Castro B, Gonzáles MS, Alcantara LC. Deep sequencing analysis of Human T cell Lymphotropic Virus type 1 (HTLV-1) long terminal repeat (LTR) 5’ region from patients with Tropical Spastic Paraparesis (TSP)/HTLV-1 associated myelopathy (HAM) and asymptomatic carriers. AIDS Res Hum Retroviruses 2015 [Epub ahead of print].

[72] Van den Hoecke S, Verhelst J, Vuylsteeke M, Saelsens X. Analysis of the genetic diversity of influenza A viruses using next-generation DNA sequencing. BMC Genomics 2015;16:79.

[73] Resende PC, Motta FC, Born PS, Miranda M, Siqueira MM. Whole-genome sequences of influenza A(H3N2) viruses isolated from Brazilian patients with mild illness during the 2014 season. Mem Inst Oswaldo Cruz 2015;110:48–50.

[74] Christiansen MT, Brown AC, Kundu S, Tutlii HJ, Williams R, Brown JR, et al. Whole-genome enrichment and sequencing of Chlamydia trachomatis directly from clinical samples. BMC Infect Dis 2014;14:591.

[75] Holmes A, Allison L, Ward M, Dallman TJ, Clark R, Fawkes A, et al. Utility of whole-genome sequencing of Escherichia coli O157 for outbreak detection and epidemiological surveillance. J Clin Microbiol 2015;53:3565–73.

[76] Perlewowski K, Popiel M, Laskus T, Nakamura S, Motooka D, Stokowy T, et al. Next-generation sequencing (NGS) in the identification of encephalitis-causing viruses: unexpected detection of human herpesvirus 1 while searching for RNA pathogens. J Virol Methods 2015;226:1–6.

[77] Santiago-Rodriguez TM, Ly M, Bonilla N, Pride DT. The human urine virome in association with urinary tract infections. Front Microbiol 2015;6:14.

[78] Xia H, Hu C, Zhang D, Tang S, Zhang Z, Kou Z, et al. Metagenomic profile of the viral communities in Rhipipecusus spp. ticks from Yunnan, China. PLoS One 2015;10:e0121609.

[79] Anmer A, Meiring TL, Bunikis I, Häggqvist S, Lindau C, Lindberg JH, et al. Comprehensive profiling of the vaginal microbiome in HIV positive women using massive parallel semiconductor sequencing. Sci Rep 2014;4:4398.

[80] Alquezar-Planas DE, Mourié T, Bruhn CA, Hansen AJ, Vitetz SN, Mørk S, et al. Discovery of a divergent HPIV4 from respiratory secretions using second and third generation metagenomic sequencing. Sci Rep 2013;3:2468.

[81] Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, et al. Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis. Genome Med 2015;7:99.

[82] Smits SL, Bodewes R, Ruiz-González A, Baumgartner W, Koopmans MP, Osterhaus AD, et al. Recovering full-length viral genomes from metagenomes. Front Microbiol 2015;6:1069.

[83] Vázquez-Castellanos JF, García-López R, Pérez-Broclo V, Pignattelli M, Moya A. Comparison of different assembly and annotation tools on analysis of simulated viral metagenomic communities in the gut. BMC Genomics 2014;15:37.

[84] Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa E, et al. A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples. Genome Res 2014;24:1180–92.

[85] Sauvage V, Cheval J, Foulonne V, Gouill MA, Pariente K, Manuguerra JC, et al. Identification of the first human gyrovirus, a virus related to chicken anemia virus. J Virol 2011;85:7948–50.

[86] Sauvage V, Foulonne V, Cheval J, Ar Gouill M, Pariente K, Dereure O, et al. Human poliovirus related to African green monkey lymphotropic poliovirus. Emerg Infect Dis 2011;17:1364–70.

[87] Xu B, Zhi N, Hu G, Wan Z, Zheng X, Liu X, et al. Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci USA 2013;110:10264–9.

[88] Naccache SN, Greninger AL, Lee D, Coffey LF, Phan T, Rein-Weston A, et al. The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns. J Virol 2013;87:1966–77.

[89] Smuts H, Kew M, Khan A, Korsman S. Novel hybrid parvovirus-like virus, NIH-COV/PHV, contaminants in silica column-based nucleic acid extraction kits. J Virol 2014;88:1398.

[90] Laupouicheung P, Petty TJ, Tiefert D, Cordey C, Docquier M, Zhodnov E, et al. Étude du virome d’une banque de produits sanguins libres par séquençage haute définition. In: SFTS, editor. Transfusion clinique et biologique. XXVIIème congrès de la Société française de transfusion sanguine. Elsevier Masson; 2015. p. 201–13.

[91] Bosch A, Pintó RM, Guix S. Human astroviruses. Clin Microbiol Rev 2014;27:1048–74.

[92] Finkbeiner SR, Holtz LR, Jiang Y, Rajendran P, Franz CJ, Zhao G, et al. Human stool contains a previously unrecognized diversity of novel astroviruses. J Virol 2009;83:1611.

[93] Holtz LR, Wylie KM, Sodergren E, Jiang Y, Franz CJ, Weinstock GM, et al. Astrovirus MLB2 virome in febrile child. Emerg Infect Dis 2011;17:2050–2.

[94] Bouzas LG, Wüthrich D, Walland J, Drögemueller C, Zurbriggen A, Vandevelde M, et al. Neotropical astrovirus in cattle with nonsuppurative encephalitis in Europe. J Clin Microbiol 2014;52:3318–24.

[95] Quan PL, Wagner TA, Briese T, Torgerson TR, Hornig M, Tashmukhamedova A, et al. Astrovirus encephalitis in boy with X-linked agammaglobulinemia. Emerg Infect Dis 2010;16:918–25.

[96] Saylor D, Thakur K, Venkatesan A. Acute encephalitis in the immunocompromised individual. Curr Opin Infect Dis 2015;28:330–6.

[97] Wunderli W, Meerbach A, Gängör T, Berger C, Greiner O, Caduff R, et al. Astrovirus infection in hospitalized infants with severe combined immunodeficiency after allogeneic hematopoietic stem cell transplantation. PLoS One 2011;6:e27483.

[98] Naccache SN, Peggs KS, Mattes MM, Fadkle R, Garson JA, Grant P, et al. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. Clin Infect Dis 2015;60:919–23.

[99] Kapoor A, Kumar A, Simantova L-P, Bhava N, Singh Chauhan L, Lee B, et al. Virome analysis of transfusion recipients reveals a novel human virus that shares genomic features with hepacviruses and pegiviruses. MBio 2015;6:e01466–15.

[100] Uch R, Fournier PE, Robert C, Blanc-Tailleur C, Galicher V, Barre R, et al. Virome analysis of transfusion recipients reveals a novel human virus that shares genomic features with hepacviruses and pegiviruses. MBio 2015;6:e01466–15.

[101] Uch R, Fournier PE, Robert C, Blanc-Tailleur C, Galicher V, Barre R, et al. Virome analysis of transfusion recipients reveals a novel human virus that shares genomic features with hepacviruses and pegiviruses. MBio 2015;6:e01466–15.
[102] Popgeorgiev N, Colson P, Thuret I, Chiarioni J, Gallian P, Raoult D, et al. Marseille virus prevalence in multitransfused patients suggests blood transmission. J Clin Virol 2013;58:722–5.

[103] Sauvage V, Livartowski A, Boizeau L, Servant-Delmas A, Lionnet F, Lefrère JJ, et al. No evidence of Marseille virus-like virus presence in blood donors and recipients of multiple blood transfusions. J Infect Dis 2014;210:2017–8.

[104] Phan TG, Desnues C, Switzer WM, Djoko CF, Schneider BS, Deng X, et al. Absence of giant blood Marseille-like virus DNA detection by polymerase chain reaction in plasma from healthy US blood donors and serum from multiply transfused patients from Cameroon. Transfusion 2015;55:1256–62.